Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hadir I. Aljohani
Observed name:
Hadir Aljohani
Institution:
Saudi Food and Drug Authority
Observed institution:
Saudi Food and Drug Authority
ORCID:
0000-0001-6990-1286
Observed ORCID:
0000-0001-6990-1286
OpenAlex ID:
A5075836471
Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports
2022
·
Eman A. Alghamdi
, Hadir Aljohani
, et al.
·
Saudi Pharmaceutical Journal
·
22
PDF
17-Alpha-Hydroxyprogesterone vs. Placebo for Preventing of Recurrent Preterm Birth: A Systematic Review and Meta-Analysis of Randomized Trials
2021
·
Abdulaali R. Almutairi
, Hadir I. Aljohani
, et al.
·
Frontiers in Medicine
·
8
PDF
Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials
2024
·
Hadir Aljohani
, Fares S. Alrubaish
, et al.
·
Therapeutic Innovation & Regulatory Science
·
4
Rwd76 Potential Risk of Acute Pancreatitis With Glp-1 Receptor Agonists
2025
·
Hadir Aljohani
·
Value in Health Regional Issues
PDF
Handling and Disposal of Hazardous Drugs: SFDA Experience
2025
·
Waad A. Altayyar
, Hadir I. Aljohani
, et al.
·
Saudi Journal of Clinical Pharmacy
Show more works
View as search
Works count:
5
Citation count:
34
H-index:
3
I10-index:
1
Year
Topic
Type